Alturos Therapeutics advancement of lead candidate ALT0135, a potentially first-in-class, orally bioavailable small molecule, into IND-enabling studies

June 18, 2026 - Alturos Therapeutics B.V., , a biopharmaceutical company focused on developing transformative therapies for ...
BioWorld

Alturos Therapeutics advances ALT-0135 into IND-enabling studies

Alturos Therapeutics BV has advanced its lead candidate, ALT-0135, into IND-enabling studies. Alturos is targeting the earliest toxic triggers in Alzheimer’s disease, particularly protein oligomers ...